Page 2 - Pharma Stocks

Biocon-BBL merger positioned to add value, says Nuvama; retains 'Buy' call

The optimism stems from the company's plan to increase its stake in Biocon Biologics (BBL), the expected consolidation of the Biologics arm, and improving fundamentals

Biocon stock tanks 6% on heavy volumes; what's triggered the sell-off?

The board of directors of Biocon are scheduled to meet on December 06, 2025, to consider and approve the proposals for investment in Biocon Biologics, an unlisted material subsidiary of the company.

Emkay predicts strong upside in Ipca Labs shares on India, export growth

Emkay Global initiated coverage of Ipca Labs shares with 'Buy' rating and a share price target of ₹1,700 -- a 19 per cent upside from current levels

US portfolio, margin expansion to drive gains for pharma major Lupin

Complex generics and better mix fuel recovery cycle

Wockhardt soars 19% on huge volumes; here's why the pharma stock rose today

The company said the United States Food and Drug Administration (USFDA) has formally accepted the New Drug Application (NDA) for its first-in-class antibiotic 'Zaynich'

Sudeep Pharma makes positive D-St debut; lists at 23% premium on bourses

Sudeep Pharma shares opened at ₹733.95, a premium of ₹140.95 or 23.8 per cent

SMS Pharma up 8% as arm gets USFDA nod for reformulated Ranitidine tablets

At 10:40 AM, SMS Pharmaceuticals share price was trading 6.77 per cent higher at ₹292.55 per share. In comparison, BSE Sensex was trading 0.73 per cent higher at 85,204.25 levels.

Sun Pharma sees Golden Cross; other pharma stocks with similar pattern

Technically, the term 'Golden Cross' has bullish implications with short-term support seen moving higher. Apart from Sun Pharma, Aurobindo Pharma and Divi's Labs too witnessed this formation recently.

Glenmark Pharma stock gains 3% on launch novel COPD treatment; details here

The company has launched Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, world's first nebulised, fixed-dose triple therapy for the treatment of Chronic Obstructive Pulmonary Disease (COPD)

Neuland, Lupin, Divi's lead domestic, CDMO surge amid US generics headwinds

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

IT, pharma to gain most from rupee fall; don't jump to buy yet: Analysts

On Monday, the rupee advanced amid reports that the RBI resumed efforts to support currency via overseas and onshore markets

Glenmark Pharma shares rise after 72% Q2 profit jump; check outlook here

Glenmark Pharma shares rose after the company reported a 72.2 per cent surge in profit after tax to ₹610.43 crore in September quarter

Ipca Labs jumps 7% after Q2 results; buy, sell or hold? Analysts suggest

Ipca Laboratories share price was trading 6.2 per cent higher at ₹1,382.60 compared to previous session's close of ₹1,302 on the NSE

Lupin share rises 2% as arm commissions Oncology block at Vizag facility

At 1:15 PM, Lupin share price was trading 1.90 per cent higher at ₹2,013.20 per share. In comparison, BSE Sensex was trading 0.91 per cent higher at 84,632.82 levels.

Nomura lifts Lupin target price on US momentum, India growth recovery

However, on the bourses, Lupin shares were trading 0.70 per cent lower at ₹1,973.50 per share at 9:30 AM. In comparison, BSE Sensex was trading 0.23 per cent lower at 83,346.45 levels.

Zydus Life Q2: Solid beat on bottom line, analysts mixed on growth outlook

Zydus Life Q2 results review: Foreign brokerage Nomura said Zydus Life delivered results above estimates, led by a stronger-than-expected performance in India.

Sun Pharma Q2 preview: Profit may dip YoY despite revenue growth; details

Sun Pharma's net profit is expected to come at ₹2,843.4 crore, marking an average decline of 3 per cent Y-o-Y, as against ₹2,932.3 crore in the year-ago period

Ajanta Pharma offers growth potential amid US generic challenges: Nuvama

With larger generic companies facing growth challenges in the US in FY27E, Ajanta Pharma, analysts believe, offers a strong investment opportunity, driven by its branded market growth

Motilal Oswal initiates with 'Buy' on Rubicon Research; check target

Motilal Oswal has initiated coverage on Rubicon Research, a pharmaceutical manufacturing company, with a 'Buy' rating

Cipla Q2 revenue grows, margins squeeze; analysts decode stock strategy

In the Q2FY26, Cipla reported consolidated revenue from operations of ₹7,589 crore, up 8 per cent year-on-year (Y-o-Y) from ₹7,051 crore in the year-ago period